Vor Biopharma (NASDAQ:VOR) Shares Up 5.3% – Here’s What Happened

Vor Biopharma Inc. (NASDAQ:VOR) shares shot up 5.3% on Wednesday. The company traded as high as $19.30 and last traded at $19.3050. 100,789 shares changed hands during trading, a decline of 91% from the average session volume of 1,068,548 shares. The stock had previously closed at $18.33.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Wedbush upped their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Vor Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.71.

Vor Biopharma Stock Performance

The stock’s 50 day simple moving average is $22.12 and its 200-day simple moving average is $17.89.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, sell-side analysts anticipate that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors have recently modified their holdings of the business. Engineers Gate Manager LP raised its position in Vor Biopharma by 37.5% in the 2nd quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after purchasing an additional 10,071 shares in the last quarter. Cannon Global Investment Management LLC acquired a new position in shares of Vor Biopharma during the first quarter worth about $209,000. Sei Investments Co. acquired a new position in shares of Vor Biopharma during the first quarter worth about $245,000. Independent Financial Group LLC purchased a new stake in shares of Vor Biopharma during the first quarter worth approximately $249,000. Finally, Bollard Group LLC increased its stake in shares of Vor Biopharma by 763.8% during the fourth quarter. Bollard Group LLC now owns 23,987 shares of the company’s stock worth $314,000 after buying an additional 21,210 shares during the period. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.